Compare Linde PLC (LIN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Linde PLC trades at $511.75 (market cap $236.74B), while State Street SPDR S&P Biotech ETF trades at $154.55. The key difference: Linde PLC pays a 1.25% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| LIN | XBI | |
|---|---|---|
Market Cap | $236.74B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $546.64 | $164.28 |
52-Week Low | $389.38 | $85.16 |
Enterprise Value | $259.10B | — |
Dividend Yield | 1.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $513.07, down 1.47% today, with strong fundamentals including 20.44% net income margin and consistent earnings beats. Technical indicators show a bearish trend with support at $509 and resistance at $520. The company maintains robust cash flow from operations of $10.35B and has raised dividends, reflecting financial health.
Outlook remains positive with 89% analyst buy ratings and a $564.80 price target, though valuation ratios are elevated. Risks include rising debt-to-asset ratio (31.63% in 2025) and potential macroeconomic pressures. The stock offers growth potential but requires monitoring of leverage and market conditions.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
